Patrick Daly

Urban Health Today

In the MANHATTAN phase 2 pilot trial, published in JAMA Oncology, researchers led by Ola Landgren, MD, PhD, concluded that combining daratumumab with the second-generation proteasome inhibitor-based triplet therapy of carfilzomib, lenalidomide, and dexamethasone yielded high rates of measurable residual disease (MRD) and progression-free survival (PFS) in patients with newly diagnosed multiple myeloma.This study followed previous reports that daratumumab improved outcomes when combined with bortezomib, lenalidomide, and dexamethasone triplet therapy in patients with newly diagnosed <a href="https://urbanhealthtoday.com/post/study-identifies-age-gender-as-prognostic-factors-in-patients-with-extramedullary-multiple-myeloma">multiple myeloma</a> who underwent high-dose melphalan chemotherapy and autologous hematopoietic cell transplantation. Comparatively, patients in this study had not undergone either chemotherapy or hematopoietic cell transplantation.<h3>Daratumumab Shows Promise in Multiple Myeloma Treatments</h3>From October 2018 to November 2019, researchers enrolled 41 evaluable patients (61% female) with a median age of 59 years (range, 30-70 years) and newly diagnosed multiple myeloma at the Memorial Sloan Kettering Cancer Center. Authors noted 20 (49%) participants had high-risk multiple myeloma.Participants received eight 28-day cycles of:<ul>
<li>Intravenous carfilzomib 20/56 mg/m2&nbsp;on days 1, 8, and 15</li>
<li>Oral lenalidomide 25 mg on days 1 through 21</li>
<li>Oral or intravenous dexamethasone 40 mg weekly&nbsp;in cycles 1 through 4, followed by 20 mg in further cycles</li>
<li>Intravenous daratumumab 16 mg/kg on days 1, 8, 15, and 22 of cycles 1 and 2; days 1 and 15 of cycles 3 through 6; and day 1 of cycles 7 and 8</li>
</ul>The primary end point was MRD negativity in bone marrow. Additional end points included safety and tolerability, response rates per International Myeloma Working Group criteria, PFS, and overall survival (OS).Participants were followed for a median of 20.3 months (95% CI, 19.2-21.9). The researchers reported 29 (71%) of 41 patients achieved the specified MRD criteria (95% CI, 54-83), leading them to judge the pilot trial a success.The median time to MRD negativity was 6 cycles (range, 1-8 cycles). The overall response rate was 100% (n=41), and the rate of very good partial or complete responses was 95% (n=39). At 11 months, authors estimated the 1-year rates for PFS and OS were 98% (95% CI, 93-100) and 100%, respectively.Grade 3 or 4 adverse events included neutropenia (n=12), rash (n=4), lung infection (n=3), and increased alanine aminotransferase level (n=2), and no patients died during the study.&ldquo;In this nonrandomized clinical trial, carfilzomib-lenalidomide-dexamethasone-<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761036s004lbl.pdf" target="_blank" rel="noopener">daratumumab</a> combination therapy was associated with high rates of MRD negativity in patients with newly diagnosed multiple myeloma and high rates of PFS,&rdquo; Landgren and colleagues concluded.View More <a href="https://urbanhealthtoday.com/page/multiple-myeloma">Recent News on Multiple Myeloma</a>

Rebecca Araujo

AI-Driven Insulin Support: Are These Tools Ready for Diabetes Care?

Diabetes

Lou Portero

Heart Rate Complexity May Predict Cognitive Decline in Older Adults

Alzheimer's & Dementia

Female Cancer Survivors Face Higher Rates of Fatigue and Depression, Study Finds

Women's Neurology

Latest News

Daratumumab Improves Multiple Myeloma Treatment Regimens

Multiple Myeloma

Daratumumab added to carfilzomib-lenalidomide-dexamethasone triplet therapy for multiple myeloma improved MRD and survival, according to a phase 2 pilot study.

About Us

Editorial Policy

Contributors & Partners

Contact Us

eNewsletters

Work With Us

Advertising

Career Center

GU Oncology Now

Blood Cancers Today

Cancer Nursing Today

DocWire News

MashupMD

Food Allergy Roundtable Discussions

Allergy

Blood Cancers

— Multiple Myeloma

Breast Cancer

Colorectal Cancer

Pancreatic Cancer

Prostate Cancer

Cancer

Gastroenterology

Heart Failure

Heart Disease Prevention

Heart Health

— Alzheimer’s Disease

Neurology

Public Health

Autoimmune Disease

Infectious Diseases

Obesity

Pediatrics

Sickle Cell Disease

Digital Health

Dermatology

Pulmonology

Video Insights

Workforce News

More

Gynecologic Cancer

Heart Disease in Women

Menopause

Reproductive Health

Women’s Neurology

Well Woman Today

Roundtables

Podcasts

Conferences

Viewpoints

Subscribe